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It has long been recognized that dietary restriction (DR)
can inhibit carcinogenesis. Recent work has not only clari-
fied the mechanisms involved, which involve the effects of
DR on circulating hormones and cytokines, but also
demonstrated molecular characteristics of tumors that
determine the extent to which they are influenced by var-
iation in host energy intake. Importantly, we and others
have also demonstrated that a subset of tumors are
growth-stimulated by excess caloric intake, and provided
strong circumstantial evidence that hyperinsulinemia is
one of the mediating factors. Metformin, a biguanide used
in cancer treatment, has been associated with reduced
cancer risk in some hypothesis-generating pharmaco-
epidemiologic studies. Laboratory studies have provided
evidence for some antineoplastic activity. However, this
activity is confined to subpopulations including subjects
who are obese and/or hyperinsulinemic. Laboratory mod-
els suggest that metformin may act in this context because
it is well-known to reduce hyperinsulinemia as a conse-
quence of its reduction of gluconeogenesis and hypergly-
cemia. At the cellular level, metformin acts to inhibit
oxidative phosphorylation, and this may provide an addi-
tional mechanism that could operate in the subset of
cancers or at-risk tissues that express the cell surface
transport molecules required for metformin entry to cells.
The ATP deficiency induced by metformin may have little
effect on some cells, an AMPK-dependent cytostatic effect
on others, and still others may suffer an energetic crisis
and necrotic death. Current research is providing addi-
tional details and mechanistic details underlying these
actions, defining the subsets patients for which biguanides
may be useful in cancer prevention or treatment, and
defining relevant doses for potential new indications.
Investigating the possibility of ‘repurposing’ metformin for
applications in oncology is ongoing as laboratory and
translational research ield data that will help to optimize
clinical trial design.
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